Не се наблюдава промяна в активността на CYP1A2, CYP3A4 или N- ацетилтрансферазата.
Results from a multiple-dose probe study assessing P450 substrates in chronic hepatitis C patients receiving once weekly PegIntron (1.5 µg/kg) for 4 weeks demonstrated an increase in activity of